Cart
sales@molnova.com
ERK-IN-3
CAS No. 2055597-12-9
ERK-IN-3( ASN007 free base )
Catalog No. M23920 CAS No. 2055597-12-9
ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 71 | In Stock |
|
| 5MG | 113 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameERK-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
-
DescriptionERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
-
In Vitro——
-
In Vivo——
-
SynonymsASN007 free base
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorERK1|ERK2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2055597-12-9
-
Formula Weight473.93
-
Molecular FormulaC22H25ClFN7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (527.50 mM; Need ultrasonic)
-
SMILESO=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1).
molnova catalog
related products
-
SCH-772984
A novel potent and selective inhibitor of ERK1/ERK2 with IC50 of 4 nM/1 nM, respectively.
-
ISRIB
ISRIB is a potent and selective PERK inhibitor with IC50 of 5 nM.
-
SMI-4a
TCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
